ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients (LYRICA)

This study is currently recruiting participants.
Verified by University of Alabama at Birmingham, June 2008

Sponsors and Collaborators: University of Alabama at Birmingham
Pfizer
Information provided by: University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00583869
  Purpose

This is a randomized, prospective, double-blind pilot study designed to evaluate the potential effectiveness of pregabalin in post-operative pain management for patients who have sustained a fracture.


Condition Intervention Phase
Post-Operative Pain
Drug: Placebo
Drug: Pregabalin
Phase 0

MedlinePlus related topics:   Fractures   

Drug Information available for:   Oxycodone    Oxycodone hydrochloride    Pregabalin    Hydrocodone    Hydrocodone bitartrate    Meperidine    Meperidine hydrochloride   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study
Official Title:   The Role of Pregabalin in the Treatment of Post-Operative Pain in Fracture Patients

Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • Amount of pain medication in morphine equivalent units used during the hospitalization. [ Time Frame: Screening - 5 - 15 minutes; Consent - 5-15 minutes; Follow-up - three 15-30-minute visits ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Secondary outcome measures will include Visual Analog Score, timing and frequency of rescue medications, Short-Form 36 Health Survey scores, and adverse events. [ Time Frame: Three 15-30-minute visits after surgery to complete SF-36 and Visual Analog Score for Pain. ] [ Designated as safety issue: No ]

Estimated Enrollment:   150
Study Start Date:   February 2007
Estimated Study Completion Date:   February 2009
Estimated Primary Completion Date:   February 2009 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Placebo Comparator
Patient to receive placebo beginning on the day of surgery until discharge.
Drug: Placebo

Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.

Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.

2: Experimental
Patient to receive 75mg PO BID pregabalin beginning on the day of surgery until discharge.
Drug: Pregabalin

Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.

Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.

3: Experimental
Patient to receive 150mg PO BID pregabalin beginning on the day of surgery until discharge.
Drug: Pregabalin

Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.

Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.


Detailed Description:

On admission, all patients who have sustained orthopaedic injuries of any type, including pelvis, will be screened. However, only those patients who will undergo a single episode of surgery during this hospitalization to surgically repair only one of their orthopaedic fractures will be interviewed by a clinical research nurse. If the patient meets all criteria for inclusion/exclusion in the study, the attending physician will consent the patient for inclusion in the study. Upon enrollment into the study, the clinical research nurse will obtain a thorough history from the patient concerning prior narcotic use, response to painful events in the past and will record details of the injury. Prior to surgery, the patient will be treated with narcotic pain medication as required in the judgment of the attending physician. The patient will then be randomized before surgery into a placebo group or pregabalin group. The attending physician will be blinded as to which study arm the patient is in.

Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive either pregabalin 75mg PO BID, pregabalin 150mg PO BID or placebo beginning on the day of surgery until discharge.

The clinical research nurse will complete a form which records the daily use of each of the post-operative pain medications. She will also ask the patient to complete a Visual Analog Scale (VAS) to assess pain each day while in the hospital.

Upon discharge, the patient will be given study medication (pregabalin, 75mg PO BID, 150mg PO BID or placebo). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.

  Eligibility
Ages Eligible for Study:   19 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • fractures requiring operative treatment during a single operative episode
  • Adult patients between the ages of 19 and 70

Exclusion Criteria:

  • prior medical history of narcotic abuse or narcotic use within 2 weeks of injury (except those given in hospital)
  • contraindications to pregabalin or narcotic analgesics
  • significant closed head injury
  • psychiatric illness requiring medical treatment
  • surgery for other injuries (splenectomy, etc)
  • history of seizures requiring current anticonvulsant therapy
  • inability or unwillingness to give informed consent
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00583869

Contacts
Contact: David A Volgas, MD     205-934-9545     David.Volgas@ortho.uab.edu    

Locations
United States, Alabama
The University of Alabama at Birmingham, Orthopaedic Trauma     Recruiting
      Birmingham, Alabama, United States, 35294
      Contact: David A Volgas, MD     205-934-9545     David.Volgas@ortho.uab.edu    
      Principal Investigator: David A Volgas, MD            

Sponsors and Collaborators
University of Alabama at Birmingham
Pfizer

Investigators
Principal Investigator:     David A Volgas, MD     The University of Alabama at Birmingham    
  More Information


Publications:

Responsible Party:   The University of Alabama at Birmingham ( David A. Volgas, MD, Associate Professor of Surgery )
Study ID Numbers:   F061204006
First Received:   December 21, 2007
Last Updated:   June 2, 2008
ClinicalTrials.gov Identifier:   NCT00583869
Health Authority:   United States: Institutional Review Board

Keywords provided by University of Alabama at Birmingham:
Post-operative Pain  
Fracture Patients  
Pregabalin  
LYRICA  

Study placed in the following topic categories:
Signs and Symptoms
Postoperative Complications
Hydrocodone
Oxycodone
Fractures, Bone
Pregabalin
Pain
Pain, Postoperative
Meperidine

Additional relevant MeSH terms:
Pathologic Processes
Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Anticonvulsants
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 31, 2008




Links to all studies - primarily for crawlers